Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 28;14(1):22532.
doi: 10.1038/s41598-024-73542-1.

Precision patient selection for improved detection of circulating genetically abnormal cells in pulmonary nodules

Affiliations

Precision patient selection for improved detection of circulating genetically abnormal cells in pulmonary nodules

Meng Tu et al. Sci Rep. .

Abstract

Circulating genetically abnormal cells (CACs) have emerged as a promising biomarker for the early diagnosis of lung cancer, particularly in patients with pulmonary nodules. However, their performance may be suboptimal in certain patient populations. This study aimed to refine patient selection to improve the detection of CACs in pulmonary nodules. A retrospective analysis was conducted on 241 patients with pulmonary nodules who had undergone pathological diagnosis through surgical tissue specimens. Utilizing consensus clustering analysis, the patients were categorized into three distinct clusters. Cluster 1 was characterized by older age, larger nodule size, and a higher prevalence of hypertension and diabetes. Notably, the diagnostic efficacy of CACs in Cluster 1 surpassed that of the overall patient population (AUC: 0.855 vs. 0.689, P = 0.044). Moreover, for Cluster 1, an integrated diagnostic model was developed, incorporating CACs, sex, maximum nodule type, and maximum nodule size, resulting in a further improved AUC of 0.925 (95% CI 0.846-1.000). In conclusion, our study demonstrates that CACs detection shows better diagnostic performance in aiding the differentiation between benign and malignant nodules in older patients with larger pulmonary nodules and comorbidities such as diabetes and hypertension. Further research and validation are needed to explore how to better integrate CACs detection into clinical practice.

Keywords: Circulating genetically abnormal cells; Early diagnosis; Lung cancer; Precision patient selection; Pulmonary nodule.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart of patients enrolled.
Fig. 2
Fig. 2
Consensus matrix heat maps for different k values. (A) k = 2. (B) k = 3. (C) k = 4. (D) k = 5. (E) k = 6. (F) k = 7. (G) k = 8. (H) k = 9. (I) k = 10. The color changes from dark blue to white, indicating a gradual decrease in consistency. The deepest blue color signifies a state of absolute consensus, where two individuals consistently cluster together. Conversely, the presence of white color indicates a perfect consensus in which the two individuals invariably group separately. k is the number of clusters. When k = 3, clearly defined boundaries in the heat map indicate high clustering stability.
Fig. 3
Fig. 3
The relative change in area under the conditional density function (CDF) curve of consensus cluster analysis when cluster number changes from k to k + 1. When k = 3, a significant decrease in the curve suggests optimal k = 3.
Fig. 4
Fig. 4
Receiver operating characteristic curve (ROC) of circulating genetically abnormal cells (CACs). (A) ROC of CACs in overall patients. (B) ROC of CACs in Cluster (1) (C) ROC of CACs in Cluster (2) (D) ROC of CACs in Cluster 3.
Fig. 5
Fig. 5
ROC of the joint diagnostic model (including CACs, sex, maximum nodule type, and maximum nodule size).

Similar articles

References

    1. Sung, H. et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71, 209–249. 10.3322/caac.21660 (2021). - PubMed
    1. Hirsch, F. R. et al. Lung cancer: Current therapies and new targeted treatments. Lancet. 389, 299–311. 10.1016/S0140-6736(16)30958-8 (2017). - PubMed
    1. Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E. & Adjei, A. A. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc.83, 584–594. 10.4065/83.5.584 (2008). - PMC - PubMed
    1. Goldstraw, P. et al. The IASLC Lung Cancer Staging Project: Proposals for revision of the TNM Stage groupings in the Forthcoming (Eighth) Edition of the TNM classification for Lung Cancer. J. Thorac. Oncol.11, 39–51. 10.1016/j.jtho.2015.09.009 (2016). - PubMed
    1. Katz, R. L. et al. Identification of circulating tumor cells using 4-color fluorescence in situ hybridization: Validation of a noninvasive aid for ruling out lung cancer in patients with low-dose computed tomography-detected lung nodules. Cancer Cytopathol.128, 553–562. 10.1002/cncy.22278 (2020). - PubMed

MeSH terms

Substances

LinkOut - more resources